Diagnostic Hybrids, Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Diagnostic Hybrids, Inc - overview
Established
1983
Location
-, OH, US
Primary Industry
Healthcare
About
Diagnostic Hybrids, Inc. specializes in innovative diagnostic solutions that enhance patient care through reliable testing. They focus on developing rapid tests and multiplex PCR platforms for diverse healthcare settings worldwide. Diagnostic Hybrids, Inc.
is a diagnostic solutions provider based in Athens, US, founded in 1983. The company was acquired by Quidel Corporation in January 2010. Since its inception, it has engaged in 2 investment deals, with the most recent being a Trade Sale worth USD 130. 00 mn, which contributed to a total raised amount of USD 130.
00 mn. The company has focused on the advancement of diagnostic technologies for improved patient outcomes. Diagnostic Hybrids offers a variety of diagnostic solutions designed to improve patient outcomes. Their leading products include the QuickVue® COVID-19 Test for at-home use and the Savanna® multiplex real-time PCR platform for point-of-care testing.
Additional offerings include VITROS® lab automation systems and the Sofia® 2 Analyzer for benchtop testing. Their products are utilized by hospitals, clinics, and laboratories in 143 countries, assisting healthcare providers with accurate diagnoses to enhance patient care. Revenue for Diagnostic Hybrids comes from direct sales and partnerships within the healthcare sector. They conduct transactions through B2B frameworks, supplying clinical laboratories and healthcare providers with diagnostic solutions, along with ongoing service agreements to enhance operational efficiency.
Notable product sales, such as the QuickVue® rapid tests and VITROS® systems, contribute significantly to their overall revenue, aligning with healthcare facilities' budgets while ensuring quality and performance. Diagnostic Hybrids plans to leverage its recent acquisition by Quidel Corporation to enhance its product offerings and expand into new markets. The company aims to introduce additional diagnostic solutions, particularly in emerging markets, to cater to increasing global healthcare demands. Following the Trade Sale in February 2010, they will utilize the proceeds to support these growth initiatives.
Expansion efforts may include targeting specific regions in Asia and Latin America, aligning product launches with ongoing healthcare developments.
Primary Industry
Healthcare
Sub Industries
Epidemiology
Website
www.dhiusa.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Diagnostic Hybrids, Inc - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Diagnostic Hybrids, Inc | - | ||||||||
| Buyout | Completed | Diagnostic Hybrids, Inc | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.